期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

白血病和淋巴瘤的靶向免疫治疗 被引量：3

暂未订购
导出
摘要 靶向免疫疗法是白血病和淋巴瘤治疗中的一种重要手段和研究热点。这种疗法的关键步骤是先找到白血病和淋巴瘤发病机制中的主要或关键致病蛋白质或在肿瘤细胞膜上所表达的抗原（这种抗原较特异或在数量和频率上较高），然后针对这种靶点通过主动、被动或过继免疫疗法进行治疗。①主动免疫疗法是用靶点蛋白制备疫苗，如用独特型（Id）免疫球蛋白（Ig）、DNA、膜蛋白脂质体（MPL）、树突状细胞等制备疫苗。
作者 王振义
机构地区 上海交通大学医学院附属瑞金医院血液科上海血液学研究所
出处 《内科理论与实践》 2008年第2期69-75,共7页 Journal of Internal Medicine Concepts & Practice
关键词 白血病 淋巴瘤 靶向免疫治疗
分类号 R733 [医药卫生—肿瘤]
  • 相关文献

参考文献37

  • 1Coiffier B.Rituximab therapy in malignant lymphoma[J],2007(25).
  • 2Starlets D;Gore Y;Binsky I.Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival[J],2006(12).
  • 3Bae J;Martinson JA;Klingemann HG.Identification of CDl9 and CD20 peptides for induction of antigenspecific CTLs against B-cell malignancies[J],2005(04).
  • 4Dijoseph JF;Dougher MM;ArrneHino DC.Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin(CMC-544)for the treatment of acute lymphoblastic leukemia,2007(11).
  • 5Tsimberidou AM;Giles FJ;Estey E.The role of gemtuzumab ozogamicin in acute leukaemia therapy[J],2006(04).
  • 6Hernández-Caselles T;Martínez-Esparza M;Pérez-Oliva AB.A study of CD33(SIGLEC-3)antigen expression and function on activated human T and NK cells:two isoforms of CD33 are generated by alternative splicing[J],2006(01).
  • 7Au WY;Leung AY;Tse EW.High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients,2008.
  • 8Tibes R;Keating MJ;Ferrajoli A.Activity of alemtuzumab in patients with CD52-positive acute leukemia[J],2006(12).
  • 9Alinari L;Lapalombella R;Andritsos L.Alemtuzumab(Campath-1H)in the treatment of chronic lymphocytic leukemia[J],2007(25).
  • 10Chapuy B;Hohloch K;Trǖmper L.Yttrium 90 ibritumomab tiuxetan(Zevalin):a new bullet in the fight against malignant lymphoma?[J],2007(01).

二级参考文献56

  • 1Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma [J]. N Engl J Med, 2003,348 (26):2609-2617.
  • 2Richardson P, Sonneveld P, Schuster MW, et al. Bortezomib vs.dexamethasone in relapsed multiple myeloma: a phase 3 randomized study [R]. Proc Am Soc Clin Oncol, 2004,Abstract No: 6502.
  • 3Connor OAO'. Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular (RL) and mantle cell lymphoma (MCL) [R]. Proc Am Soc Clin Oncol, 2004, Abstract No: 6582.
  • 4Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma [J]. N Engl J Med, 1993,328( 14): 1002-1006.
  • 5McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric antiCD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program [J]. J Clin Oncol,1998,16(8): 2825-2833.
  • 6Marcus R, Imrie K, Belch A, et al.An international multi-centre,randomized, open-label, phase Ⅲ trial comparing Rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage Ⅲ / Ⅳ follicular non-Hodgkin's lymphoma [R].ASH, 2003, Abstract No: 87.
  • 7Hiddemann W, Dreyling MH,Forstpointner R, et al. Combined immuno-chemotherapy (R-CHOP)significantly improves time to treatment failure in first line therapy of follicular lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)[R]. ASH, 2003, Abstract No: 352.
  • 8Hochster HS, Weller E, Ryan T, et al.Results of E1496: a phase Ⅲ trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL) [R]. Proc Am Soc Clin Oncol, 2004, Abstract No: 6502.
  • 9Dreyling MH, Forstpointner R, Repp R,et al. Combined immuno-chemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma: final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [R]. ASH, 2003,Abstract No: 351.
  • 10Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases eventfree survival and response duration compared with the standard weekly x 4schedule [J]. Blood, 2004,103 (12):4416-4423.

共引文献12

同被引文献27

  • 1张旗,宋振岚.三氧化二砷联合化疗治疗难治性多发性骨髓瘤21例[J].白血病．淋巴瘤,2005,14(3):168-169. 被引量：7
  • 2李勇,张湘茹,孙燕.非小细胞肺癌的靶向治疗进展[J].癌症进展,2007,5(2):151-157. 被引量：18
  • 3Schirrmacher V, Griesbach A, Ahlert T. Antitumor effects of newcastle disease virus in vivo: Local versus systemic effects [ J]. Int J Oncol, 2001,18(5 ) :945 -952.
  • 4Fabian Z, Csatary CM, Szeberenyi J,et al. p53 - independent endoplasmic reticulum stress - mediated cytotoxicity of a newcastle disease virus strain in tumor cell lines[J]. J Virol,2007,81 (6) :2817 -2830.
  • 5Estevez C, King D, Seal B, et al. Evaluation of Newcastle disease virus chimeras expressing the Hemagglutinin - Neuraminidase protein of velogenie strains in the context of a mesogenie recombinant virus backbone [J]. Virus Res,2007,129(2) :182 -190.
  • 6Phuangsab A, Lorence RM, Reichard KW,et al. Newcastle disease virus therapy of human tumor xenografts : Antitumor effects of local or systemic administration [ J ]. Cancer Lett, 2001,172 ( 1 ) :27 - 36.
  • 7Vigil A,Park MS, Martinez O,et al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus [ J ]. Cancer Res, 2007,67 ( 17 ) :8285 - 8292.
  • 8Ptihler F, Willuda J, Puhlmann J, et al. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes[ J]. Gene Ther ,2008 ,15 (5) :371 - 383.
  • 9Schirrmacher V, Haas C, Bonifer R,Ahlert T,Gerhards R,Ertel C.Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus[J].Gene Ther, 1999, 6(1): 63-73.
  • 10Vigil A, Park MS, Martinez O,Chua MA,Xiao S,Cros JF,et al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus[J]. Cancer Res, 2007, 67(17): 8285-8292.

引证文献3

二级引证文献4

内科理论与实践
2008年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部